Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Niharika B. Mettu"'
Autor:
Al B Benson, Anirban Maitra, Milind Javle, Michael Overman, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B Mettu, Edwin R Parra, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background The immunosuppressive desmoplastic stroma of pancreatic cancer represents a major hurdle to developing an effective immune response. Preclinical studies in pancreatic cancer have demonstrated promising anti-tumor activity with Bruton tyros
Externí odkaz:
https://doaj.org/article/50d0394471cc4ce4983fa47de5d9edeb
Autor:
Sunil Sharma, Leonardo Faoro, Ann M. Kapoun, Robert Stagg, Kathleen N. Moore, John H. Strickler, Ignacio Garrido-Laguna, Johanna C. Bendell, Susanna V. Ulahannan, Niharika B. Mettu
Supplementary Figure from A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0de96f43f7ae6497732fe19348b6ec89
https://doi.org/10.1158/1078-0432.22482125.v1
https://doi.org/10.1158/1078-0432.22482125.v1
Autor:
Sunil Sharma, Leonardo Faoro, Ann M. Kapoun, Robert Stagg, Kathleen N. Moore, John H. Strickler, Ignacio Garrido-Laguna, Johanna C. Bendell, Susanna V. Ulahannan, Niharika B. Mettu
Purpose:TIGIT (T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) is a co-inhibitory receptor of T-cell and natural killer cell activity. Targeting TIGIT with or without PD-1/PD-L1 checkpoint inhibiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e76e713af1bdec49cf695a488bc4a37
https://doi.org/10.1158/1078-0432.c.6530828
https://doi.org/10.1158/1078-0432.c.6530828
Autor:
Sunil Sharma, Leonardo Faoro, Ann M. Kapoun, Robert Stagg, Kathleen N. Moore, John H. Strickler, Ignacio Garrido-Laguna, Johanna C. Bendell, Susanna V. Ulahannan, Niharika B. Mettu
Supplementary Table from A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::138679cb0435228e1140f3f060da27c4
https://doi.org/10.1158/1078-0432.22482116.v1
https://doi.org/10.1158/1078-0432.22482116.v1
Autor:
Francesca Rigiroli, Jocelyn Hoye, Reginald Lerebours, Peijie Lyu, Kyle J. Lafata, Anru R. Zhang, Alaattin Erkanli, Niharika B. Mettu, Desiree E. Morgan, Ehsan Samei, Daniele Marin
Publikováno v:
European Radiology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ff36c7602cc88c3750f5d361ab6a964
https://doi.org/10.1007/s00330-023-09532-0
https://doi.org/10.1007/s00330-023-09532-0
Autor:
Aung Naing, Alain P. Algazi, Gerald S. Falchook, Benjamin C. Creelan, John Powderly, Seth Rosen, Minal Barve, Niharika B. Mettu, Pierre L. Triozzi, John Hamm, Gongfu Zhou, Chris Walker, Zhiwan Dong, Manish R. Patel
Publikováno v:
Cancer, vol 129, iss 1
BackgroundTargeting programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO1) pathways is an appealing option for cancer treatment.MethodsThe open-label, phase 1/2 ECHO-203 study evaluated the safety, tolerability, and efficacy of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed381cf9a07119057cea27eba75562f8
https://escholarship.org/uc/item/1z41q6t4
https://escholarship.org/uc/item/1z41q6t4
Autor:
Mathias Meyer, Peijie Lyu, Reginald Lerebours, Kyle Lafata, Daniele Marin, Yuqin Ding, Cai Li, Francesca Rigiroli, Ehsan Samei, Fides R. Schwartz, Jocelyn Hoye, Sheng Luo, Niharika B. Mettu, Desiree E. Morgan, Sabino Zani
Publikováno v:
Radiology. 301:610-622
Background Current imaging methods for prediction of complete margin resection (R0) in patients with pancreatic ductal adenocarcinoma (PDAC) are not reliable. Purpose To investigate whether tumor-related and perivascular CT radiomic features improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::516ba0497324f7d6c583bab2889c17ef
https://doi.org/10.1148/radiol.2021210699
https://doi.org/10.1148/radiol.2021210699
Autor:
Timothy A. Yap, Siddhartha Yadav, Benjamin Herzberg, Benedito A. Carneiro, Elisa Fontana, Martin Højgaard, Michael J. Pishvaian, Ruth Plummer, Theresa L. Werner, Vaibhav Sahai, Stephanie Lheureux, Elizabeth K. Lee, Niharika B. Mettu, Gregory M. Cote, Joseph D. Schonhoft, Victoria Rimkunas, Ian M. Silverman, Marisa Wainszelbaum, Gerson Peltz, Adrian J. Fretland, Kezhen Fei, Danielle Ulanet, Insil Kim, Maria Koehler, Ezra Rosen, Michael Cecchini
Publikováno v:
Cancer Research. 83:CT018-CT018
Introduction: ATRi and PARPi combinations kill tumor cells via synergistic modulation of complementary DDR pathways but clinical utility is limited by overlapping toxicities. A genome-wide CRISPR-Cas9 screen identified DDR alterations that sensitize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5440534684331a320c7059e7bfb12f85
https://doi.org/10.1158/1538-7445.am2023-ct018
https://doi.org/10.1158/1538-7445.am2023-ct018
Autor:
David B. Solit, Niharika B. Mettu, Shannon J. McCall, Mallika Dhawan, Priyanka J. Bobbili, Maral DerSarkissian, Jasmina Ivanova, Bhakti Arondekar, Jane Chang, Alexander Niyazov, Jocelyn Lee, Risha Huq, Michelle Green, Michelle Turski, Aruna Muthukumar, Tracy Guo, Mei Sheng Duh, William K. Oh
Publikováno v:
Cancer Research. 83:930-930
Background: Limited information is available about treatments and clinical outcomes among men with metastatic castration-resistant prostate cancer (mCRPC) whose tumors harbor DNA damage repair (DDR) mutations. Methods: This retrospective chart review
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e0e7ab07055576b16cec972dea9a933
https://doi.org/10.1158/1538-7445.am2023-930
https://doi.org/10.1158/1538-7445.am2023-930
Autor:
Ignacio Garrido-Laguna, John H. Strickler, Johanna C. Bendell, Sunil Sharma, Leonardo Faoro, Robert J. Stagg, Ann M. Kapoun, Kathleen N. Moore, Susanna Varkey Ulahannan, Niharika B. Mettu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(5)
Purpose:TIGIT (T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) is a co-inhibitory receptor of T-cell and natural killer cell activity. Targeting TIGIT with or without PD-1/PD-L1 checkpoint inhibiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d5f5608788e3e72d8ae0f6303586b43
https://pubmed.ncbi.nlm.nih.gov/34844977
https://pubmed.ncbi.nlm.nih.gov/34844977